These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 3538860)

  • 21. Cisplatin nephrotoxicity in a patient with a single kidney.
    Udeani GO; Singh K; Mullane MR; Lad TE
    Ann Pharmacother; 1996; 30(7-8):782-6. PubMed ID: 8826561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Nephrotoxicity of cisplatin].
    Herody M
    Ann Urol (Paris); 1992; 26(2):128-31. PubMed ID: 1616302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
    Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
    BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
    Caglar K; Kinalp C; Arpaci F; Turan M; Saglam K; Ozturk B; Komurcu S; Yavuz I; Yenicesu M; Ozet A; Vural A
    Nephrol Dial Transplant; 2002 Nov; 17(11):1931-5. PubMed ID: 12401849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
    Skinner R
    Pediatr Nephrol; 2018 Feb; 33(2):215-225. PubMed ID: 28434047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
    Dimery IW; Legha SS
    J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal and electrolyte disturbances associated with cisplatin.
    Blachley JD; Hill JB
    Ann Intern Med; 1981 Nov; 95(5):628-32. PubMed ID: 7027859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative adverse effect profiles of platinum drugs.
    McKeage MJ
    Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria.
    Santos NA; Bezerra CS; Martins NM; Curti C; Bianchi ML; Santos AC
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):145-55. PubMed ID: 17396264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
    BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
    Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
    Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
    Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
    Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal and metabolic toxicities of cancer chemotherapy.
    Schilsky RL
    Semin Oncol; 1982 Mar; 9(1):75-83. PubMed ID: 7200263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
    Ding DC
    Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):64-6. PubMed ID: 1396050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
    Goren MP
    Med Pediatr Oncol; 2003 Sep; 41(3):186-9. PubMed ID: 12868117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin nephrotoxicity.
    Arany I; Safirstein RL
    Semin Nephrol; 2003 Sep; 23(5):460-4. PubMed ID: 13680535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for renal toxicity after inpatient cisplatin administration.
    Galfetti E; Cerutti A; Ghielmini M; Zucca E; Wannesson L
    BMC Pharmacol Toxicol; 2020 Mar; 21(1):19. PubMed ID: 32122396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.